Immunocompetent Rats
Immunocompetent Rats - Related Videos
02:28
Bioluminescence Imaging of an Immunocompetent Mouse Model for Glioblastoma
0 Views •
2025
Source: Clark, A.J., et al. Bioluminescence Imaging of an Immunocompetent Animal Model for Glioblastoma. J. Vis. Exp. (2016)This video demonstrates bioluminescence imaging to track glioblastoma progression in an immunocompetent mouse model, using luciferase-expressing tumor cells and luciferin to quantify tumor growth non-invasively.
04:46
Intrabronchial Instillation of Streptococcus pneumoniae in Immunocompetent Rodent Models
0 Views •
2025
This video demonstrates the establishment of lung infection in an immunocompetent rodent model via intubation and installation of bacterial suspensions into lung lobes. This model enables antibacterial efficacy studies in immunocompetent animals.
01:22
Development of Immunocompetence
0 Views •
2024
The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later. The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation. Subsequent T...
09:17
Bioluminescence Imaging of an Immunocompetent Animal Model for Glioblastoma
0 Views •
Cited by 13 •
2016
GL261 glioma cells provide a useful immunocompetent animal model of glioblastoma. The goals of this protocol are to demonstrate proper techniques for monitoring intracranial tumor growth using in vivo bioluminescence imaging, and to verify the utility of luciferase-modified GL261 cells for studying tumor immunology and immunotherapeutic approaches for treating glioblastoma.
09:17
A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
0 Views •
Cited by 17 •
2017
A method for establishing lung infections in immunocompetent rodents is described. With proficiency, this method can be performed quickly and easily to induce stable infection with many isolates of S. pneumoniae, H. influenzae, P. aeruginosa, K. pneumoniae and A. baumannii.
FAQs
Host immune cells can recognize an implanted material and initiate inflammation or a foreign-body reaction. These responses may also influence vascularization and tissue repair, changing how an engineered construct integrates with surrounding tissue. Evaluating these interactions helps distinguish a material’s intended biological effect from limitations caused by immune activation, which is central to assessing biocompatibility.
Immunocompetent rats preserve immune interactions that immunodeficient models do not fully represent. This comparison can show whether a device, construct, or therapy performs only when immune activity is absent or remains effective during a complete host response. The added information is valuable for identifying safety limitations and judging whether findings may support further translational development.
Researchers should consider inflammation, foreign-body reactions, vascularization, tissue repair, and rejection as distinct possible outcomes. Their relative presence depends on the material and experimental context, so a single measure may not capture the full host response. Examining these outcomes together can clarify whether an implant is tolerated, promotes regeneration, or creates an adverse biological interaction.
They are useful when a study must assess how an engineered material, device, tissue construct, drug delivery system, implant, or regenerative therapy interacts with an intact host response. Their use is especially relevant when immune recognition could affect efficacy or safety. Results can reveal therapeutic effects alongside biological limitations that might be missed in models lacking normal immune interactions.
The model allows investigators to evaluate engineered tissues and regenerative therapies while immune cells remain capable of recognizing the intervention. This setting can reveal whether treatment is associated with tissue repair, vascularization, inflammation, foreign-body responses, or rejection. Such observations help researchers assess both the desired regenerative outcome and the host reactions that may restrict performance.
Findings can inform judgments about biocompatibility, therapeutic effects, and safety limitations before further translational development. A favorable response may support continued investigation, whereas inflammation, rejection, or an excessive foreign-body reaction can identify concerns requiring attention. Because the model retains immune interactions, it contributes evidence about how engineered systems may behave in a physiologically relevant host context.